1 – 2 of 2 jobs
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is Deramiocel ( CAP-1002), our lead cell therapy in late-stage development
Deadline Date: Tuesday 19 May 2026 Requirement: Ballistic Missile Defence (BMD) Feasibility Study Location of Performance: Off-Site Cost Not to Exceed: 2026 BASE NTE: 171,900 EUR. Period of Performance: 2026 BASE: 18 June (tentative) 2026 to 31
Recommended jobs for you
